Read time: 4 minutes Lung cancers that test positive for the RET biomarker are often treated with targeted therapy. While this type of treatment has improved the duration and
Read time: 4 minutes Advances in targeted therapies have allowed us to treat some types of lung cancer with mutations in specific genes (for example, EGFR, KRAS, and RET). This has
Read time: 4 minutes Lung cancer screening guidelines were first issued by the United States Preventive Services Task Force in 2013 to help doctors find lung cancer in its earliest
Read Time: 5 minutes Approximately 4% of patients diagnosed with non-small cell lung cancer (NSCLC) will have their tumors test positive for an ALK biomarker. This means the ALK
Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive
LUNGevity blogs share personal stories, research updates, scientific meeting takeaways, policy news, and much more. Joining our Email List will help you stay updated on these
Finding lung cancer in its early stages significantly increases the chance of successfully treating and even curing the disease. Low-dose CT is the current approved approach to
Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The
The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of